谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Phase III Randomized Study of Taselisib or Placebo with Fulvestrant in Estrogen Receptor-Positive, PIK3CA-mutant, HER2-negative, Advanced Breast Cancer: the SANDPIPER Trial.

S. Dent,J. Cortes,Y-H Im,V Dieras,N. Harbeck,I. E. Krop,T. R. Wilson,N. Cui,F. Schimmoller,J. Y. Hsu, J. He,M. De Laurentiis,S. Sousa,P. Drullinsky,W. Jacot

Annals of Oncology（2020）

引用 110|浏览75
关键词
PIK3CA mutations,taselisib,PI3K inhibitors,advanced breast cancer
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要